Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02576522 : Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Age > 18 years

- Karnosky performance status (KPS) =70

- All Solid tumor (esclusion SCLC and Germinal tumors)

- Controlled primary tumor

- Controlled other metastatic site

- Single metastatic lesion at diagnosis

- Lesions = 2.1 cm in maximum diameter (4 cm3), < 3 cm conditioning mass effect or
neurological deficits or massive aedema, unknown primary tumor

- Estimated survival = 3 months.

- Written informed consent

Exclusion Criteria:

- Prior WBRT

- KPS = 70

- Other primary cancer

- Pregnant women
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02576522      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740